PDCD1 and neoplasm: The triple combination of chidamide + celecoxib + anti-PD-1 antibody significantly reduced tumor volume, with primary tumor eradication in 5 out of 8 mice, and 75% survival at day 60 after tumor implantation (Fig. 4A,D–H).